10055 Barnes Canyon Road
San Diego, CA 92121
Tel: (619) 353-0300
About Element Biosciences
At Element Biosciences, our mission is to empower the scientific community with more freedom and flexibility to accelerate our collective impact on humanity. Our proprietary approach to improving the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation, and biochemistry to drastically decrease the run cost and capital cost while delivering high sequencing data quality. Founded in 2017, our headquarters is located in San Diego, California, with additional operations located in the San Francisco Bay area.
46 articles about Element Biosciences
Element Biosciences Announces Over 100 Commercial Orders of its AVITI System and Surpasses Q2 Sales Goals
Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, announced it has exceeded 100 orders of the AVITI System.
Element Biosciences, Inc. announced the appointment of veteran life science executive Yaron Hakak as Senior Vice President of Corporate and Business Development.
Element Biosciences Announces AVITI FIT, a Suite of Products to Empower More Researchers with Flexible Genomic Solutions
Element Biosciences, Inc. today unveiled five new products to better serve customers' low to medium-throughput needs and expand the functionality and versatility of its benchtop sequencer.
Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the formation of its Scientific Advisory Board with four leading experts on genomics, oncology, chemistry, and biology.
Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, announced an expanded commercial partnership with Agilent Technologies to cooperate in selling Element and Agilent products, starting in the United States.
Element Biosciences Announces Genomics Industry Veteran as Senior Vice President of Marketing and Product Management
Element Biosciences, Inc. today announced the appointment of Edwin Hauw as senior vice president of marketing and product management.
Element Biosciences, Inc. announced it is now leveraging a new Amazon Omics feature, Ready2Run workflows, to provide simple, powerful, and cost-effective analysis workflows.
Element Signs Multiple Global Distributors to Bring the Power of AVITI™ to Customers Around the World
Element Biosciences, Inc. has signed distribution agreements with companies based in Israel, South Korea, Australia, and the United Arab Emirates to bring its AVITI System to more customers around the world.
Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples
Phase Genomics, Inc and Element Biosciences , the developer of an innovative DNA sequencing platform disrupting genomics, today released new details of their first collaboration leveraging Phase Genomics’ proprietary OncoTerra™ cytogenomics platform and the Element AVITI System for next generation sequencing (NGS).
Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits
Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced a partnership to demonstrate the capabilities of the Bio-Rad SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI™ Benchtop Sequencer.
Element Biosciences, Inc. will present details about its new Avidity Cloudbreak™ technology and the company's innovation roadmap at the Advances in Genome Biology and Technology General Meeting Feb. 6-9, 2023, in Hollywood, FL.
Element Biosciences, Inc announced the promotion of Shawn Levy , PhD, to Chief Scientific Officer and Senior Vice President of Applications.
Element Biosciences, Inc.— the developer of an innovative DNA sequencing platform disrupting genomics — announced a new throughput-based option for its AVITI System that provides the highest quality sequencing on a benchtop for as low as $200 a genome, or $2 per gigabase.
Element Biosciences, Inc. announced that Element CEO and Co-Founder Molly He will speak at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 3:30 p.m. Pacific Time at the Westin St. Francis hotel in San Francisco.
Element Biosciences, Inc. announced Avidity Cloudbreak technology, improvements to chemistry kits for the current Element AVITI™ System that reduce run times and enable even more applications.
Element Biosciences, Inc. announced the availability of its Element LoopSeq long-read sequencing technology kits for AVITI, giving the Element AVITI System the power of both short- and long-read sequencing on the same instrument.
Element Biosciences Delivers 1 Billion Reads and Provides Industry's Lowest Cost for Single-Cell Sequencing
Element Biosciences, Inc. announced updated specifications to their AVITI System, increasing the platform's specifications from 800 million reads per flow cell to 1.0 billion reads per flow cell*, further reducing the price per Gigabase.
Element Biosciences Welcomes Former ThermoFisher Executive Shelly Peariso to their Growing Commercial Team
Element Biosciences, Inc. announced they are adding an industry veteran to their commercial team.
Element Biosciences Inc., developer of the Element AVITITM System, a new and disruptive DNA sequencing platform, announced it will implement no price increases to the entire range of AVITI reagents, including the sequencing kit, the AdeptTM and ElevateTM kits.
Element Science Announces First Patient Save with Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
Element Science, an innovative health technology company pioneering a next-generation digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, today announced the first patient save from a successful defibrillation early in the enrollment of the Investigational Device Exception (IDE) Study of its Jewel Patch Wearable Cardioverter Defibrillator (P-WCD).